CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for WooGene B&G CO., LTD is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

WooGene B&G CO., LTD
230, Jeongmunsongsan-ro, Yanggam-myeon
Phone: +82 313520185p:+82 313520185 HWASEONG, 18628  South Korea Ticker: 018620018620
Business Summary
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Company’s products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Jae GuKang 53 3/30/2023 3/25/2014
Co-Chief Executive Officer, Director Seok JinKang 80 3/30/2023
Vice President, Director Gyeong DeokYang 59 1/1/2012
4 additional Officers and Directors records available in full report.

Business Names
Business Name
018620
WooGene B&G CO., LTD

General Information
Number of Employees: 119 (As of 9/30/2018)
Outstanding Shares: 28,887,171 (As of 12/31/2023)
Shareholders: 13,251
Stock Exchange: KDQ
Fax Number: +82 313521488


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024